Genentech, a San Francisco-based biotech company, has decided to more than double its investment in a new drug manufacturing ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing ...

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 ...

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory ...

Zydus Lifesciences plans to acquire a majority stake in Ardelyx Inc. for $2.2-2.5 billion, funding the deal through a ₹5,000 ...

Booster Therapeutics (Germany) focuses on developing small-molecule proteasome activators for neurodegenerative disease using ...

The Artisan Mid Cap Fund outpaced the Russell Midcap Growth Index in Q4 2025 despite a modest negative absolute return. Read ...

Kura Oncology holds a strong cash position with Komzifti FDA approval and frontline AML expansion potential. Read why KURA ...

Researchers identified a polyphosphate kinase that converts nucleotide precursors into all four RNA nucleotides in one step. Using inexpensive polyphosphate, the enzyme enables low-cost, efficient NTP ...

Neurizon Therapeutics has completed registered trademark protection across all priority global pharmaceutical markets. ...

Shares of Rapt Therapeutics ( RAPT +63.95%) surged on Tuesday after the immunology specialist struck a deal to be acquired by ...